Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) Patents (Class 424/172.1)
-
Publication number: 20140255404Abstract: The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension.Type: ApplicationFiled: October 23, 2012Publication date: September 11, 2014Applicant: PH TherapeuticsInventor: Allan Lawrie
-
Publication number: 20140255427Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.Type: ApplicationFiled: August 14, 2012Publication date: September 11, 2014Applicant: MorphoSys AGInventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
-
Publication number: 20140255341Abstract: Therapies effective for the treatment and prevention of cancer and other diseases are disclosed. These methods include the administration of therapeutically effective amounts of agents that increase the local production of effector cell-attracting chemokines within tumor lesions, with concomitant suppression of local production of undesirable chemokines that attract regulatory T(reg) cells. These methods include administering to the subject therapeutically effective amounts of a Toll-like receptor (TLR) agonist or other activator of NF-KB pathway in combination with a blocker of prostaglandin synthesis or a blocker of prostaglandin signaling, in combination with a type-1 interferon, or in combination with both a blocker of prostaglandin synthesis or signaling and with a type-1 interferon.Type: ApplicationFiled: July 23, 2012Publication date: September 11, 2014Inventors: Pawel Kalinski, Ravikumar Muthuswamy
-
Publication number: 20140255956Abstract: Provided herein are, inter alia, methods of diagnosing myocardial autoimmunity in subjects by detecting the presence of autoantibodies to cardiac antigens in the subjects.Type: ApplicationFiled: May 27, 2014Publication date: September 11, 2014Inventors: Myra A. Lipes, Lizbeth Cornivelli, Venkata Siva Rama Krishnam Raju Gottumukkala
-
Publication number: 20140255346Abstract: Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), MOG peptides (MOGps), proteolipid protein (PLP), and PLP peptides (PLPps). Stimulating PBMCs from patients with MS by CNS antigens cause B-lymphocytes to produce antibodies specific for CNS antigen, and causes T-lymphocytes to produce T-lymphocyte-specific cytokines, including interferon gamma (IFN-y), interleukin-2 (IL-2), or interleukin-17 (IL-17). In contrast, stimulating PBMCs from subjects without MS do not produce such responses.Type: ApplicationFiled: May 3, 2012Publication date: September 11, 2014Applicant: Cellular Technology, Ltd.Inventors: Stefanie Kuerten, Paul Lehmann
-
Patent number: 8828397Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: September 14, 2012Date of Patent: September 9, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Publication number: 20140248288Abstract: The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The compositions are prepared by vacuum induction/crucible melting together the components and casting the melted mixture in a preheated mild steel/copper mold. In certain embodiments, the compositions of the invention are particularly useful for forming medical devices for implantation into a body of a patient.Type: ApplicationFiled: October 5, 2012Publication date: September 4, 2014Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Prashant N. Kumta, Da-Tren Chou, Daeho Hong, Partha Saha
-
Publication number: 20140248287Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: January 30, 2014Publication date: September 4, 2014Applicants: SYNTONIX PHARMACEUTICALS, INC., DYAX CORP.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Patent number: 8821880Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: GrantFiled: September 9, 2009Date of Patent: September 2, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Patent number: 8821873Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.Type: GrantFiled: October 3, 2013Date of Patent: September 2, 2014Assignee: Biogen Idec Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez
-
Publication number: 20140241988Abstract: The present invention relates to compositions and methods for the prevention and treatment of atrial fibrillation. In particular, the present invention provides therapeutic agents for the treatment and prevention of persistent and permanent atrial fibrillation and prevention of progression of atrial fibrillation to permanent atrial fibrillation.Type: ApplicationFiled: January 31, 2014Publication date: August 28, 2014Applicant: The Regents of The University of MichiganInventor: José Jalife
-
Publication number: 20140242081Abstract: The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.Type: ApplicationFiled: July 18, 2011Publication date: August 28, 2014Applicants: MICROMET AG, MEDIMMUNE, LLCInventors: Scott Hammond, Patricia Ryan, Song Ren, Petra Lutterbuese, Maria Amann
-
Publication number: 20140242093Abstract: In one aspect, the present invention relates to methods for increasing, decreasing or maintaining the innate immune response in a mammalian subject comprising modulating the expression of DUX4-fl, or modulating the expression of beta-defensin 3 (DEFB103). In another aspect, the present invention relates to methods for increasing, decreasing or maintaining myogenesis or muscle differentiation in a mammalian subject comprising modulating the expression of beta-defensin 3 (DEFB103). In additional aspects, the present invention involves diagnostic methods based on assessment of identified biomarkers.Type: ApplicationFiled: July 27, 2012Publication date: August 28, 2014Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Stephen J. Tapscott, Linda Geng
-
Publication number: 20140242072Abstract: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: BIOINVENT INTERNATIONAL ABInventor: Markus Hansson
-
Publication number: 20140242087Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.Type: ApplicationFiled: February 27, 2014Publication date: August 28, 2014Applicant: H. LUNDBECK A/SInventors: Simon Glerup Pedersen, Ulrich Bolcho, Kimmo Jensen, Anders Nykjaer
-
Publication number: 20140242074Abstract: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating 5 conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.Type: ApplicationFiled: August 30, 2012Publication date: August 28, 2014Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Kirk P. Conrad, Mark S. Segal
-
Publication number: 20140241984Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.Type: ApplicationFiled: December 23, 2013Publication date: August 28, 2014Applicant: UNITED ARAB EMIRATES UNIVERSITYInventor: OMAR EL-AGNAF
-
Publication number: 20140241987Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.Type: ApplicationFiled: February 28, 2013Publication date: August 28, 2014Applicant: United Arab Emirates UniversityInventor: Omar EL-AGNAF
-
Patent number: 8815240Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: GrantFiled: March 18, 2009Date of Patent: August 26, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20140234330Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor E form a heteromeric receptor complex that is biologically active, and that IL-17C activity requires the IL-17RA-IL-17RE heteromeric receptor complex. Antagonists of the IL-17RA-IL-17RE heteromeric receptor complex are disclosed, as well as various methods of use.Type: ApplicationFiled: July 20, 2012Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Alison L. Budelsky, Jennifer E. Towne, Yu Zhang, Lori Siegel, Antony Symons
-
Publication number: 20140234299Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists.Type: ApplicationFiled: January 17, 2014Publication date: August 21, 2014Applicants: Imperial College of Science, Technology and Medicine, Biogen Idec MA Inc.Inventors: Roy Lobb, Charles Pusey, Andrew Allen
-
Publication number: 20140234342Abstract: The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and/or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to treat or prevent diseases, e.g. cancer, infection, autoimmune diseases, inflammatory diseases and the like.Type: ApplicationFiled: June 21, 2012Publication date: August 21, 2014Applicants: INNATE PHARMA, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Emilie Narni-Mancinelli, Sophie Ugolini, Eric Vivier
-
Publication number: 20140234341Abstract: The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of ?-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.Type: ApplicationFiled: April 18, 2012Publication date: August 21, 2014Applicant: KYOTO UNIVERSITYInventors: Hirohito Tsubouchi, Akio Ido, Tsutomu Chiba, Akira Shimizu
-
Publication number: 20140234343Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.Type: ApplicationFiled: November 12, 2012Publication date: August 21, 2014Inventors: Bong Hee Lee, Kyung Hee Byun
-
Publication number: 20140234340Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.Type: ApplicationFiled: November 30, 2011Publication date: August 21, 2014Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
-
Patent number: 8808701Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: December 19, 2012Date of Patent: August 19, 2014Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
-
Publication number: 20140227291Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.Type: ApplicationFiled: August 12, 2011Publication date: August 14, 2014Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giasi, Ulrich Ebert, Chung-Ming Hsieh
-
Publication number: 20140227290Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: ApplicationFiled: February 17, 2014Publication date: August 14, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Publication number: 20140227292Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.Type: ApplicationFiled: September 9, 2013Publication date: August 14, 2014Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
-
Publication number: 20140227186Abstract: Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise a carbohydrate, insulin and/or a glutathione; and (b) the at least one agent to be delivered to the CNS. Methods of treatment and diagnosing CNS disorders utilising the nanoparticle delivery systems and related screening methods are also disclosed.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Inventors: Thomas Rademacher, David K. Male
-
Publication number: 20140227294Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).Type: ApplicationFiled: December 23, 2013Publication date: August 14, 2014Applicant: ABBVIE INC.Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. DiGiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
-
Publication number: 20140227293Abstract: The present invention provides methods and compositions for the treatment and prevention of angiogenesis, or cancer, e.g., metastatic cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression. In particular, the present invention provides methods and compositions for the treatment and prevention of cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression which is a soluble extracellular domain IGPR-1. Another aspects relates to methods and compositions comprising a IGPR-1 polypeptide or functional fragment thereof to promote angiogenesis in a subject in need thereof, e.g., for treatment of infarcts, retinopathy, AMD and the like.Type: ApplicationFiled: June 29, 2012Publication date: August 14, 2014Applicant: TRUSTEES OF BOSTON UNIVERSITYInventor: Nader Rahimi
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Patent number: 8802099Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.Type: GrantFiled: November 10, 2011Date of Patent: August 12, 2014Assignee: National Jewish HealthInventors: Erwin W. Gelfand, Meiqin Wang
-
Publication number: 20140220041Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.Type: ApplicationFiled: September 19, 2012Publication date: August 7, 2014Applicant: University of the Witwatersrand, JohannesburgInventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
-
Publication number: 20140220004Abstract: Provided herein are compositions containing an antibody or antigen-binding antibody fragment that specifically binds to metallothionein 2 (MT2) protein, and compositions containing an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, and optionally, one or more anti-inflammatory agents and/or analgesics. Also provided are methods of decreasing pain in a mammal that include administering to the mammal an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, in an amount sufficient to decrease the level of extracellular MT2 protein or neutralize a function of extracellular MT2 protein in the mammal, thereby decreasing pain in the mammal.Type: ApplicationFiled: June 1, 2012Publication date: August 7, 2014Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Nader Ghasemlou, Christian A. Von Hehn, Clifford J. Woolf
-
Publication number: 20140220039Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic ? cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic ? cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic ? cells.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: BioCrine ABInventor: Per-Olof BERGGREN
-
Publication number: 20140219919Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: CSL LimitedInventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON
-
Publication number: 20140220036Abstract: The present invention provides methods of inhibiting a tau protein such as h-tau42 or a biologically active fragment, derivative or analog thereof, methods of treating a disease caused by a tau protein such as h-tau42, and methods to identify agents that may inhibit a tau protein such as h-tau42. The methods for identifying an agent effective to inhibit a tau protein may feature administering an agent; and observing either i) a reduction in biological activity of the tau protein or a biologically active fragment, derivative or analog thereof or ii) a reduction in phosphorylation of the tau protein or a biologically active fragment, derivative or analog thereof.Type: ApplicationFiled: February 1, 2013Publication date: August 7, 2014Inventors: Rodolfo R. Llinas, Herman Moreno, Mutsuyuki Sugimori
-
Publication number: 20140220040Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: ApplicationFiled: April 17, 2014Publication date: August 7, 2014Applicant: ARCA BIOPHARMA, INC.Inventors: Arie Abo, Minke Binnerts
-
Publication number: 20140220038Abstract: The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of LRP1 by means of certain agents, including a recombinant expression vector, an RNAi, an antibody, a siRNA etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall exposed to ischaemia. The invention also relates to the use of said molecules in the treatment and/or prevention of the changes in the metabolism of calcium and cardiac remodeling associated with ischaemia.Type: ApplicationFiled: June 29, 2012Publication date: August 7, 2014Inventors: Concepción Vicenta Llorente Cortés, Lina Badimon Maestro
-
Publication number: 20140220000Abstract: The invention relates to methods for treating disorders by targeting CLIP molecules and MHC. The methods are useful for treating, inhibiting the development of, or otherwise dealing with diseases such as HIV, blood vessel proliferative disorder, cancer and fibrosis.Type: ApplicationFiled: April 4, 2012Publication date: August 7, 2014Applicants: Scott & White Healthcare, The Texas A&M University SystemInventors: Martha Karen Newell, Cassie L. Harvey, Richard Tobin
-
Publication number: 20140220037Abstract: The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellinType: ApplicationFiled: November 22, 2013Publication date: August 7, 2014Applicants: Cleveland Clinic Foundation, Cleveland BioLabs, Inc.Inventors: Andrei Gudkov, Robert Fairchild
-
Publication number: 20140212435Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.Type: ApplicationFiled: January 15, 2014Publication date: July 31, 2014Applicant: Xencor, Inc.Inventors: Gregory L. Moore, John Desjarlais
-
Publication number: 20140212421Abstract: The invention provides compositions and methods that enhance the delivery of large macromolecules (i.e., greater than 10 kDa), such as antigen-binding polypeptides, across tight junctions. Such methods and compositions are particularly useful for delivering therapeutic antigen-binding polypeptides to the CNS, via intranasal administration, for the treatment of neurological disorders.Type: ApplicationFiled: February 26, 2014Publication date: July 31, 2014Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Valerie Hulmann-Cottier, David Urech, Esther Furrer
-
Publication number: 20140212438Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.Type: ApplicationFiled: April 3, 2014Publication date: July 31, 2014Applicant: Yeda Research and Development Co., Ltd.Inventors: Rony SEGER, Dana Chuderland
-
Publication number: 20140212436Abstract: The present invention relates to rapid clearance molecules that bind target antigens and Fc?RIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.Type: ApplicationFiled: January 15, 2014Publication date: July 31, 2014Inventors: Gregory L. Moore, John Desjarlais, Matthew Bernett
-
Publication number: 20140212417Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: ApplicationFiled: September 24, 2012Publication date: July 31, 2014Applicant: Ablynx N.V.Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
-
Publication number: 20140212437Abstract: The present invention relates to compositions and methods for the prevention and treatment of atrial fibrillation. In particular, the present invention provides therapeutic agents for the treatment and prevention of persistent and permanent atrial fibrillation and prevention of progression of atrial fibrillation to permanent atrial fibrillation.Type: ApplicationFiled: January 31, 2014Publication date: July 31, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Jose Jalife
-
Patent number: 8790648Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.Type: GrantFiled: May 15, 2012Date of Patent: July 29, 2014Assignee: Amgen Inc.Inventors: Joel Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim